key: cord-0762232-9ammqrp5
authors: Vest, Alec; Houdeshell, Holly; Clark, Cyndi; Ghorpade, Vikram; Case, Rob; Schrecker, Joshua; Hardison, Matthew
title: eP333: Tracking the emergence of SARS-CoV-2 variants of concern in vaccinated and unvaccinated patients
date: 2022-03-31
journal: Genetics in Medicine
DOI: 10.1016/j.gim.2022.01.368
sha: 4e5bff4d718019de901595a0b94202433d7d43a1
doc_id: 762232
cord_uid: 9ammqrp5

nan

Hospital, the standard of care is to obtain clinical rGS through a reference laboratory. In addition to standard of care testing, patients are offered the opportunity to undergo internal research rGS through "The Institute for Genomic Medicine Use of Rapid Genomic Profiling in Pediatric Patients" study. Results from both the clinically ordered rGS and the internal research rGS are compared, thus allowing the opportunity to investigate differences in reported results. In the clinical setting, much attention is given to the depth of sequencing for probands undergoing rGS; however, parental sequencing depth is often given little thought by ordering clinicians. Given that de novo inheritance is considered strong evidence for pathogenicity with confirmation of maternity and paternity (PS2) and moderate evidence of pathogenicity without confirmation of maternity and paternity (PM6) in the ACMG/AMP Standards and Guidelines for the Interpretation of Sequence Variants, incorrect labeling of an inherited variant as de novo has significant potential for harm. Potential for this harm is further increased by recent efforts to reduce the use of orthogonal confirmation of variants detected by next generation sequencing. Case presentation: Here, we present a series of false positive, de novo variants reported by a clinical reference laboratory. These same variants were correctly identified as inherited from a parent through internal research rGS which sequenced parental samples at a much greater depth. We compared reported de novo variants on 10 reports from the reference laboratory to those identified by internal research rGS. Seven different variants from 4 trios were identified by the clinical reference laboratory as de novo when they were, in fact, inherited. Parental mean depth of coverage for these cases was low overall with a mean of 11.96x and a range of 9.57x-14.17x. In contrast, internal research rGS sequenced parental samples with a mean depth of coverage of 31.86x and a range of 23.36x-39.81x (Table 1 ), significantly higher than that of the clinical reference laboratory. As a result, these variants were all correctly identified as inherited from an unaffected parent, not de novo as suggested by the clinical reference laboratory. We detected an average of 25 phenotype related and 285 non-phenotype related rare (gnomAD popmax filtering allele frequency, 95% confidence <0.001), heterozygous in proband, missense and loss of function variants in genes known to cause autosomal dominant disorders per case, all of which were actually inherited from one parent. Of these variants, we observed an average of 1 and 17 true de novos which were phenotype related and not, respectively. Conclusion: The accuracy of variant calling is directly affected by the depth of coverage in next generation sequencing based technologies such as genome sequencing. Specifically, low depth of coverage in parental samples can lead to missed variant calls in parents and subsequently false positive identification of "de novo" variants in probands leading to inaccurate variant interpretation. Assuming a minimum of 3 reads required to call a variant as present in a sample, and a parental variant allele frequency of 50%, then at a parental depth of 10x, we would expect to see 1 false positive de novo call related to phenotype and 14 false positive de novo calls unrelated to phenotype per case. At this depth of coverage, the positive predictive value for any given de novo variant identified is 48% for variants related to phenotype and 52% for variants unrelated to phenotype. By increasing the mean sequencing depth to 19x, it becomes very unlikely (<0.1%) to see any false positive de novo calls and the positive predictive value for a called de novo becomes~100%. Thus, this case series brings attention to the potential pitfalls of low sequencing depth in parental samples, and highlights the importance of adequate sequencing depth for all members of a trio undergoing rGS. Importantly, because the burden of these false positive de novos is a function of the number of observed variants that are rare in population databases, families from ancestral backgrounds underrepresented in such databases, especially those of African ancestry, are likely to be most affected. Tracking the emergence of SARS-CoV-2 variants of concern in vaccinated and unvaccinated patients Alec Vest 1 , Holly Houdeshell 1 , Cyndi Clark 1 , Vikram Ghorpade 1 , Rob Case 1 , Joshua Schrecker 1 , Matthew Hardison 1 1 Aegis Sciences Corporation Introduction: Emerging infectious organisms, such as SARS-CoV-2, create public health crises that demand real-time tracking and ongoing surveillance of new variants to monitor changes in transmissibility, virulence, and effectiveness of vaccines. Aegis Sciences BioPharma Laboratory has sequenced over 250,000 RT-PCR-confirmed SARS-CoV-2 positive specimens from patients across the United States and Puerto Rico and evaluated the emergence, community spread, and dominance of variants of concern (VOC) in vaccinated and unvaccinated individuals. Methods: Through a collaboration with Walgreens, Aegis Sciences BioPharma Laboratory performs COVID-19 testing on patient specimens from all over the United States. Patients schedule appointments via an online portal, submit health data and vaccination status for physician review, and perform sociallydistanced, self-collections from the Walgreens pharmacy drive-through while being observed by a trained clinical team member. SARS-CoV-2 positive specimens with an average cycle threshold (Ct) value of <30 were selected for sequencing based on their state's testing volume and overall population statistics. SARS-CoV-2 genome sequencing and lineage analysis was performed via an optimized workflow using the Illumina COVIDSeq RUO Kits with the NovaSeq 6000 sequencer and the Illumina DRAGEN COVID Lineage Application. The prevalence and spread of variants of concern was evaluated in both vaccinated and unvaccinated patients. Results: Since March 2021, Aegis has submitted over 250,000 sequences from COVID-19 positive patient specimens to the GISAID database, including 437 unique SARS-CoV-2 lineages. Starting in May, the patient's vaccination status was captured to help monitor vaccine effectiveness and compare variant spread in vaccinated versus unvaccinated individuals. In total, 170,019 patient specimens with a vaccination status have been sequenced. From March to May 2021, Alpha (B.1.1.7) cases increased from 8% to 66%. At Alpha's peak (May to Mid-June), the average rate of breakthrough cases neared 10% of total sequenced samples. In early June, Delta (B.617.2) cases accounted for only 3% of samples but quickly rose to 60% while Alpha declined from 38% to 6%. From July to

Delta's AY sublineages emerged and have since become more prevalent than their B.617.2 parent lineage. Of note, AY.25 (33.54%), AY.44 (37.69%), and AY.39 (36.79%) also have increased vaccine breakthrough rates with the highest

Conclusion: Monitoring viral variant trends and epidemiology through community surveillance programs is critical during a public health crisis. The data generated through these collaborations is vital to tracking viral evolution and understanding changes in transmissibility, virulence, and vaccine effectiveness. Aegis' sequencing and analysis of >250,000 SARS CoV-2 specimens will continue to contribute to our understanding of COVID-19 for years to come

Variant calls are managed within the Bionano Access software, where filters are applied to enable the prioritization of variants likeliest to have biologic consequence. Here we demonstrate a comprehensive and lab-ready workflow for constitutional disorders-spanning whole genome OGM data analysis, alignment and annotation using GRCh38, variant evaluation, and classification. Methods: For constitutional genomic analysis, OGM data is collected and analyzed with the Bionano Access software and the de novo assembly variation calling method. Maps are assembled based on direct fluorescent labeling of a 6 bp sequence motif resulting in specific patterns across the genome (similar to chromosomal banding analysis), maps representing different alleles are aligned to a sequence reference based on GRCh19 or GRCh38 after in silico marking of the labeled sequence motif to identify variants. Variants are further queried for overlap against a database of assay matched, phenotypically healthy controls. Results: To generate a list of potentially relevant variants, we apply a workflow to filter based on insertion/deletion size (≥1.5 kbp), rare in an internal controls database (≤1% presence), and having overlap with a gene. The resulting prioritized variant list presents an average of~20-30 variants for further analysis and classification in most cases. We add these to a curation list, and evaluate each in a variant classifier visualization tool. Each variant is captured as aligned to GRCh38, showing properties such as size and putative impact to genes. Multiple analysts may classify variants independently. Finally, a supervisor can reconcile analyst records to adjudicate classifications, record any large-scale genomic irregularities, and download a complete research report. Conclusion: OGM data is well suited to identify manifold variants relevant to constitutional genetic disease research. The analytical approach annotates thousands of genome

eP335 Genetic testing for APOB, LDLR, PCSK9, and LDLRAP1 suggest that FH testing may be underutilized

Familial hypercholesterolemia is thought to be one of the most common monogenic diseases, with data estimating the prevalence as 1 in 220 to 1 in 313 individuals. While the diagnosis of FH can be made clinically, many diagnostic criteria include genetic testing as a component in the diagnostic algorithm. Methods: In our laboratory, we have performed next-generation panel sequencing on reportedly healthy adults in two independent testing cohorts: one being screened for the four genes associated with FH (APOB, LDLR, PCSK9, and LDLRAP1) and another screened for the CDC Tier 1 genes

Of the 2,779 individuals tested using the CDC Tier 1 panel, 19 individuals were found to have diagnostic findings for FH (~1 in 146 individuals). The prevalence of FH in our testing cohort suggests this disorder may be more common than expected. Overall, diagnostic findings were returned for 43 individuals

Several studies have shown an association of higher levels of LDL-C in HeFH in individuals with a null variant in the LDLR gene when compared to those individuals with missense changes in the gene. Additionally, individuals with pathogenic variants detected were found to have higher odds ratios for coronary artery disease compared individuals without identified FH variants; null alleles in LDLR were reported to have an odds ratio (OR) for coronary artery disease (CAD) of 9.5 and individuals with missense variants in LDLR were reported to have an OR for CAD of 3.5. Of the 43 samples for which a diagnostic finding was returned for FH in our testing cohorts, 25 were returned a result of a pathogenic/likely pathogenic variant in the LDLR gene